Latest reported quarter: ANNUAL, ended Dec 2025
Quarter 2026/Q2
| Line item | 2025 ANNUAL | 2024 ANNUAL | 2023 ANNUAL | 2022 ANNUAL | 2021 ANNUAL |
|---|---|---|---|---|---|
| Total Revenue as Reported | $824.84M | $786.44M | $756.99M | $712.54M | $645.41M |
| Total Operating Revenue | $824.84M | $786.44M | $756.99M | $712.54M | $645.41M |
| Cost of Revenue | $603.22M | $589.18M | $593.81M | $568.24M | $502.95M |
| Gross Profit | $221.62M | $197.27M | $163.19M | $144.30M | $142.46M |
| Operating Expense | $147.81M | $148.60M | $119.73M | $98.35M | $93.58M |
| Selling and Admin Expenses | $147.81M | $148.60M | $119.73M | $98.35M | $93.58M |
| Operating Profit | $73.81M | $48.66M | $43.46M | $45.95M | $48.88M |
| Net Non-Operating Interest Income (Expense) | -$12.68M | -$15.30M | -$20.77M | -$11.57M | -$11.19M |
| Non-Operating Interest Expense | $12.68M | $15.30M | $20.77M | $11.57M | $11.19M |
| Other Income (Expense) | -$108.38M | -$6.44M | -$6.31M | -$1.05M | $132.79M |
| Special Income (Charges) | -$110.12M | -$6.44M | -$14.54M | -$6.45M | $132.52M |
| -Less:Restructuring and Mergern & Acquisition | $2.24M | $6.44M | $14.54M | $6.16M | $0.00 |
| -Less:Other Special Charges | $107.89M | – | – | $295,000.00 | – |
| Other Non-Operating Income (Expenses) | $1.75M | – | $8.24M | $5.40M | $268,000.00 |
| Pretax Profit | -$47.25M | $26.92M | $16.38M | $33.32M | $170.48M |
| Tax | -$9.89M | $5.24M | $451,000.00 | $4.53M | $34.95M |
| Net Profit | -$37.35M | $21.68M | $15.93M | $28.79M | $135.54M |
| Profit from Continuing Operations | -$37.35M | $21.68M | $15.93M | $28.79M | $135.54M |
| Net Income to Parent Company | -$37.35M | $21.68M | $15.93M | $28.79M | $135.54M |
| Net Income to Common Stockholders | -$37.35M | $21.68M | $15.93M | $28.79M | $135.54M |
| Basic EPS | -$2.50 | $1.47 | $1.16 | $2.38 | $11.41 |
| Diluted EPS | -$2.50 | $1.44 | $1.14 | $2.33 | $11.06 |
| Dividend Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Gain on Sale of Property/Plant/Equipment | – | – | – | – | $132.52M |
No comments yet — be the first to weigh in on DCO.